April 5, 2018 / 12:28 PM / in 20 days

BRIEF-Antares Pharma Says FDA Accepts Resubmission To CRL For Xyosted NDA

Reuters Staff

1 Min Read

April 5 (Reuters) - Antares Pharma Inc:

* ANNOUNCED FDA ACKNOWLEDGED RECEIPT OF RESUBMISSION TO CRL RECEIVED IN CONNECTION WITH XYOSTED NEW DRUG APPLICATION

* FDA CONSIDERED RESUBMISSION A COMPLETE, CLASS 2 RESPONSE & HAS ASSIGNED USER FEE GOAL DATE OF SEPT. 29, 2018 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.